Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frank Rolfs

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
Chemico-Biological Interactions|February 17, 2024
Loss of VRK1 alters the nuclear phosphoproteome in the DNA damage response to doxorubicinElena Navarro-Carrasco, Aurora Campos-Díaz, Eva Monte-Serrano, et al.
International Journal of Molecular Sciences|May 11, 2024
VRK1 Regulates Sensitivity to Oxidative Stress by Altering Histone Epigenetic Modifications and the Nuclear Phosphoproteome in Tumor CellsElena Navarro-Carrasco, Eva Monte-Serrano, Aurora Campos-Díaz, et al.
Cancer Research|November 5, 2015
Nrf2 Activation Promotes Keratinocyte Survival during Early Skin Carcinogenesis via Metabolic AlterationsFrank Rolfs, Marcel Huber, Andreas Kuehne, et al.
Molecular Systems Biology|May 26, 2019
INKA, an integrative data analysis pipeline for phosphoproteomic inference of active kinasesRobin Beekhof, Carolien van Alphen, Alex A Henneman, et al.
Molecular Systems Biology|April 14, 2019
INKA, an integrative data analysis pipeline for phosphoproteomic inference of active kinasesRobin Beekhof, Carolien van Alphen, Alex A Henneman, et al.
Cell Reports|May 20, 2023
Multi-omics analysis reveals distinct non-reversion mechanisms of PARPi resistance in BRCA1- versus BRCA2-deficient mammary tumorsJinhyuk Bhin, Mariana Paes Dias, Ewa Gogola, et al.
Nature|August 10, 2022
Truncated FGFR2 is a clinically actionable oncogene in multiple cancersDaniel Zingg, Jinhyuk Bhin, Julia Yemelyanenko, et al.
Nature|September 1, 2022
Publisher Correction: Truncated FGFR2 is a clinically actionable oncogene in multiple cancersDaniel Zingg, Jinhyuk Bhin, Julia Yemelyanenko, et al.
Cancer Cell|May 30, 2025
The pan-cancer proteome atlas, a mass spectrometry-based landscape for discovering tumor biology, biomarkers, and therapeutic targetsJaco C Knol, Mengge Lyu, Franziska Böttger, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Chemico-Biological Interactions|February 17, 2024
Loss of VRK1 alters the nuclear phosphoproteome in the DNA damage response to doxorubicinElena Navarro-Carrasco, Aurora Campos-Díaz, Eva Monte-Serrano, et al.
International Journal of Molecular Sciences|May 11, 2024
VRK1 Regulates Sensitivity to Oxidative Stress by Altering Histone Epigenetic Modifications and the Nuclear Phosphoproteome in Tumor CellsElena Navarro-Carrasco, Eva Monte-Serrano, Aurora Campos-Díaz, et al.
Cancer Research|November 5, 2015
Nrf2 Activation Promotes Keratinocyte Survival during Early Skin Carcinogenesis via Metabolic AlterationsFrank Rolfs, Marcel Huber, Andreas Kuehne, et al.
Molecular Systems Biology|May 26, 2019
INKA, an integrative data analysis pipeline for phosphoproteomic inference of active kinasesRobin Beekhof, Carolien van Alphen, Alex A Henneman, et al.
Molecular Systems Biology|April 14, 2019
INKA, an integrative data analysis pipeline for phosphoproteomic inference of active kinasesRobin Beekhof, Carolien van Alphen, Alex A Henneman, et al.
Cell Reports|May 20, 2023
Multi-omics analysis reveals distinct non-reversion mechanisms of PARPi resistance in BRCA1- versus BRCA2-deficient mammary tumorsJinhyuk Bhin, Mariana Paes Dias, Ewa Gogola, et al.
Nature|August 10, 2022
Truncated FGFR2 is a clinically actionable oncogene in multiple cancersDaniel Zingg, Jinhyuk Bhin, Julia Yemelyanenko, et al.
Nature|September 1, 2022
Publisher Correction: Truncated FGFR2 is a clinically actionable oncogene in multiple cancersDaniel Zingg, Jinhyuk Bhin, Julia Yemelyanenko, et al.
Cancer Cell|May 30, 2025
The pan-cancer proteome atlas, a mass spectrometry-based landscape for discovering tumor biology, biomarkers, and therapeutic targetsJaco C Knol, Mengge Lyu, Franziska Böttger, et al.
Pageof 2